Nikon (7731) · InitiativeAdvanced
Entry into contract manufacturing of cells and other products for regenerative medicine
First written in FY2016. 1 of 2 entries say "Achieved", first in FY2016. Latest entry: FY2018.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Launch of a Regenerative Medicine CDMO and Contract Cell Manufacturing BusinessA theme 15 companies write about · 1 as a headwind · 22 as a tailwind
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 15 companies compared. The sentences above are computed from all 15.Full recordFilings, disclosures and news, newest first
- FY2018AdvancedAnnual report
「In this business, we also entered into a contract manufacturing agreement with Athersys, Inc. of the United States for the commercialisation of MultiStem, a somatic stem-cell regenerative medicine product undergoing clinical trials in Japan for the treatment of cerebral infarction.」
In the contract manufacturing business for cells and other products for regenerative medicine, we entered into a contract manufacturing agreement with Athersys for the commercialisation of MultiStem. - FY2016AchievedAnnual report
「To enter the contract manufacturing business for cells and other products for regenerative medicine, we partnered with industry leader Lonza and established (株)ニコン・セル・イノベーション with 100% funding from the company.」
The partnership with Lonza and establishment of a wholly owned company put a concrete structure in place for entry into the business.